Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1990 Sep;64(3):186–189. doi: 10.1136/hrt.64.3.186

Ischaemic left ventricular failure: evidence of sustained benefit after 18 months' treatment with xamoterol.

E Vigholt-Sørensen 1, O Faergeman 1
PMCID: PMC1024369  PMID: 1976339

Abstract

The long term effects of treatment with xamoterol in 14 patients aged 44-73 with mild to moderate heart failure as a result of ischaemic heart disease are reported. After 18 months' treatment with xamoterol, patients were assessed in a randomised double blind crossover comparison of xamoterol (200 mg twice a day) and placebo, each given for one month. Compared with placebo, xamoterol significantly increased exercise duration and work done on a bicycle ergometer and reduced the maximum exercise heart rate. Assessment of symptoms and activities at 12 months by visual analogue and Likert scales showed a trend towards the relief of symptoms of breathlessness and tiredness and an improvement in activity. There was an improvement in the clinical signs of heart failure and no haemodynamic deterioration over a 12 month period as assessed by ejection fraction. The improvement in exercise tolerance, symptoms, and activities was sustained for 18 months without side effects or development of tolerance.

Full text

PDF
186

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrios L., Geboers J., Piessens J. H., de Geest H. Effects of xamoterol a new beta-adrenoceptor partial agonist, in patients with angina pectoris. Eur J Clin Pharmacol. 1986;29(6):667–671. doi: 10.1007/BF00615956. [DOI] [PubMed] [Google Scholar]
  2. Cleland J. G., Dargie H. J., Ford I. Mortality in heart failure: clinical variables of prognostic value. Br Heart J. 1987 Dec;58(6):572–582. doi: 10.1136/hrt.58.6.572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Colucci W. S., Alexander R. W., Williams G. H., Rude R. E., Holman B. L., Konstam M. A., Wynne J., Mudge G. H., Jr, Braunwald E. Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med. 1981 Jul 23;305(4):185–190. doi: 10.1056/NEJM198107233050402. [DOI] [PubMed] [Google Scholar]
  4. Glover D. R., Wathen C. G., Murray R. G., Petch M. C., Muir A. L., Littler W. A. Are the clinical benefits of oral prenalterol in ischaemic heart failure due to beta blockade? A six month randomised double blind comparison with placebo. Br Heart J. 1985 Feb;53(2):208–215. doi: 10.1136/hrt.53.2.208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Lambertz H., Meyer J., Erbel R. Long-term hemodynamic effects of prenalterol in patients with severe congestive heart failure. Circulation. 1984 Feb;69(2):298–305. doi: 10.1161/01.cir.69.2.298. [DOI] [PubMed] [Google Scholar]
  6. McCaffrey P. M., Riddell J. G., Shanks R. G. The selectivity of xamoterol, prenalterol, and salbutamol as assessed by their effects in the presence and absence of ICI 118,551. J Cardiovasc Pharmacol. 1988 May;11(5):543–551. doi: 10.1097/00005344-198805000-00006. [DOI] [PubMed] [Google Scholar]
  7. McKee P. A., Castelli W. P., McNamara P. M., Kannel W. B. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971 Dec 23;285(26):1441–1446. doi: 10.1056/NEJM197112232852601. [DOI] [PubMed] [Google Scholar]
  8. Molajo A. O., Bennett D. H. Effect of xamoterol (ICI 118587), a new beta1 adrenoceptor partial agonist, on resting haemodynamic variables and exercise tolerance in patients with left ventricular dysfunction. Br Heart J. 1985 Jul;54(1):17–21. doi: 10.1136/hrt.54.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Nuttall A., Snow H. M. The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist. Br J Pharmacol. 1982 Oct;77(2):381–388. doi: 10.1111/j.1476-5381.1982.tb09309.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation. 1988 Apr;77(4):721–730. doi: 10.1161/01.cir.77.4.721. [DOI] [PubMed] [Google Scholar]
  11. Pouleur H., Rousseau M. F., Mengeot P., Veriter C., Vincent M. F., Brasseur L. A. Improvement of global and regional left ventricular function in patients with previous myocardial infarction by a new beta 1 adrenoceptor partial agonist, ICI 118,587. Eur Heart J. 1982 Dec;3 (Suppl 500):123–127. [PubMed] [Google Scholar]
  12. Rao A. K., Pratt C., Berke A., Jaffe A., Ockene I., Schreiber T. L., Bell W. R., Knatterud G., Robertson T. L., Terrin M. L. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988 Jan;11(1):1–11. doi: 10.1016/0735-1097(88)90158-1. [DOI] [PubMed] [Google Scholar]
  13. Rousseau M. F., Pouleur H., Vincent M. F. Effects of a cardioselective beta 1 partial agonist (corwin) on left ventricular function and myocardial metabolism in patients with previous myocardial infarction. Am J Cardiol. 1983 May 1;51(8):1267–1274. doi: 10.1016/0002-9149(83)90297-7. [DOI] [PubMed] [Google Scholar]
  14. Swerdlow C. D., Winkle R. A., Mason J. W. Determinants of survival in patients with ventricular tachyarrhythmias. N Engl J Med. 1983 Jun 16;308(24):1436–1442. doi: 10.1056/NEJM198306163082402. [DOI] [PubMed] [Google Scholar]
  15. Vigholt-Sørensen E., Faergeman O., Snow H. M. Effects of xamoterol, a beta 1 adrenoceptor partial agonist, in patients with ischaemic dysfunction of the left ventricle. Br Heart J. 1989 Nov;62(5):335–341. doi: 10.1136/hrt.62.5.335. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES